ReviewNaunyn-Schmiedeberg's archives of pharmacology2006
Small molecule vanilloid TRPV1 receptor antagonists approaching drug status: can they live up to the expectations?
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 39 citations in OpenAlex.
- Systematic Analysis of Monoterpenes: Advances and Challenges in the Treatment of Peptic Ulcer Diseases.Biomolecules · 2020Review
- TRP channels: potential drug target for neuropathic pain.Inflammopharmacology · 2016Review
- Geraniol-a flavoring agent with multifunctional effects in protecting the gastric and duodenal mucosa.Naunyn-Schmiedeberg's archives of pharmacology · 2014Article
- TRP channels and analgesia.Life sciences · 2013Review
- Acid-evoked Ca2+ signalling in rat sensory neurones: effects of anoxia and aglycaemia.Pflugers Archiv : European journal of physiology · 2009Article
- The activation of transient receptor potential vanilloid receptor subtype 1 by capsaicin without extracellular Ca2+ is involved in the mechanism of distinct substance P release in cultured rat dorsal root ganglion neurons.Naunyn-Schmiedeberg's archives of pharmacology · 2008Article
- Differential modulation of agonist and antagonist structure activity relations for rat TRPV1 by cyclosporin A and other protein phosphatase inhibitors.Naunyn-Schmiedeberg's archives of pharmacology · 2008Article
- ThermoTRP channels in nociceptors: taking a lead from capsaicin receptor TRPV1.Current neuropharmacology · 2008Article
- Human keratinocytes are vanilloid resistant.PloS one · 2008Article
- Pharmacological characterisation of capsaicin-induced relaxations in human and porcine isolated arteries.Naunyn-Schmiedeberg's archives of pharmacology · 2007Article
- Transient receptor potential (TRP) channels as drug targets.Naunyn-Schmiedeberg's archives of pharmacology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cloning of the transient receptor potential vanilloid type-1 (TRPV1) receptor initiated the discovery of potent small molecule antagonists, many of which are in preclinical phase or already undergoing clinical trials. While animal experiments imply a therapeutic value for these compounds as novel analgesic-antiphlogistic drugs, new findings with TRPV1 deficient (trpv1 -/-) mice signal troubles for TRPV1 antagonists as clinical research gains impetus. An emerging concept with important implications for drug development is that TRPV1 may be differentially regulated under physiological and pathological conditions. If so, it is conceivable that such TRPV1 ligands can be synthesized that specifically target TRPV1 in diseased (e.g. inflamed or neoplastic) tissues but spare TRPV1 that subserves its physiological functions in healthy organs. This review explores the current status of this field and seeks an answer to the question how these new discoveries could be factored into TRPV1 drug discovery and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.